Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings

Journal of Cellular Biochemistry

Volumn 91, Issue 3, 2004, Pages 443-458

  Meuillet, Emmanuelle ^a   Stratton, Suzanne ^b   Cherukuri, Durga Prasad ^a   Goulet, Anne Christine ^a   Kagey, Jacob ^a   Porterfield, Bruce ^a   Nelson, Mark A ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Anti carcinogenic activity; Morbidity; Prostate cancer; Selenium; Selenomethionine; Signaling

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SELENIUM; ALPHA TOCOPHEROL; ORGANOSELENIUM DERIVATIVE; SODIUM SELENITE;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; HUMAN; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CLASSIFICATION; DRUG SCREENING; MALE; METABOLISM; ORGANIZATION AND MANAGEMENT; PROSTATE TUMOR;

CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; ELIGIBILITY DETERMINATION; HUMANS; MALE; MODELS, BIOLOGICAL; ORGANOSELENIUM COMPOUNDS; PROSTATIC NEOPLASMS; SELENIUM; SODIUM SELENITE; VITAMIN E;

EID: 2442691034     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10728     Document Type: Review

References (111)

1. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJ, Gordon JI, Humphrey PA, Milbrandt J. 2001. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7(1):101-107.
2. Adachi T, Kar S, Wang M, Carr BI. 2002. Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol 192(2):151-159.
3. Avanzini P, Vinceti M, Ilariucci F, Masini L, D'Inca M, Vivoli G. 1995. Serum selenium concentrations in patients with newly diagnosed lymphoid malignancies. Haematologica 80:505-511.
4. Baker A, Payne CM, Briehl MM, Powis G. 1997. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57:5162-5167.
5. Bansal MP, Mukhopadhyay T, Scott J, Cook RG, Mukhopadhyay R, Medina D. 1990. DNA sequencing of a mouse liver protein that binds selenium: Implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 11:2071-2073.
6. Bar-Noy S, Gorlatov SN, Stadtman TC. 2001. Overexpression of wild type and SeCys/Cys mutant of human thioredoxin reductase in E. coli: The role of selenocysteine in the catalytic activity. Free Radic Biol Med 30(1):51-61.
7. Berggren MM, Mangin JF, Gasdaka JR, Powis G. 1999. Effect of selenium on rat thioredoxin reductase activity: Increase by supranutritional selenium and decrease by selenium deficiency. Biochem Pharmacol 57:187-193.
8. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB. 2001. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166:2034-2038.
9. Buchanan BB, Schurmann P, Decottignies P, Lozano RM. 1994. Thioredoxin: A multifunctional regulatory protein with a bright future in technology and medicine. Arch Biochem Biophys 314:257-260.
10. Burk RF. 1983. Biological activity of selenium. Annu Rev Nutr 3:53-70.
11. Clark LC, Marshall JR. 2001. Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 57:185-187.
12. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr., Park HK, Sanders BB, Jr., Smith CL, Taylor JR. 1996. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. J Am Med Assoc 276:1957-1963.
13. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. 2002. Cancer survival among US Whites and minorities: A SEER (surveillance, epidemiology, and end results) program population-based study. Arch Intern Med 162:1985-1993.
14. Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. 1988. Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 128:515-523.
15. Combs GF, Jr., Gray WP. 1998. Chemopreventive agents: Selenium. Pharmacol Ther 79(3):179-192.
16. Combs GF, Jr., Clark LC, Turnbull BW. 2001. An analysis of cancer prevention by selenium. Biofactors 14:153-159.
17. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. 2003. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63(1):52-59.
18. Drago JR, Nesbitt JA, Badalament RA, Smith J. 1988. Chemotherapy and vitamin E in treatment of Nb rat prostate tumors. In Vivo 2:399-401.
19. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Jr., Slate EH, Fischbach LA, Marshall JR, Clark LC. 2002. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev 11:630-639.
20. Edlefsen KL, Mandelson MT, McIntosh MW, Andersen MR, Wagner EH, Urban N. 1999. Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use? Am J Prev Med 17:87-90.
21. el-Bayoumy K. 1994. Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis 15:2395-2420.
22. el-Bayoumy K, Upadhyaya P, Desai DH, Amin S, Hecht SS. 1993. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenicity in mouse lung by the synthetic organoselenium compound, 1,4-phenylene-bis(methylene) selenocyanate. Carcinogenesis 14:1111-1113.
23. Esaki N, Nakamura T, Tanaka H, Suzuki T, Morino Y, Soda K. 1981. Enzymatic synthesis of selenocysteine in rat liver. Biochemistry 20(15):4492-4496.
24. Esworthy RS, Baker MA, Chu FF. 1995. Expression of selenium-dependent glutathione peroxidase in human breast tumor cell lines. Cancer Res 55(4):957-962.
25. Fernandez-Banares F, Cabre E, Esteve M, Mingorance MD, Abad-Lacruz A, Lachica M, Gil A, Gassull MA. 2002. Serum selenium and risk of large size colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol 97:2103-2108.
26. Fex G, Pettersson B, Akesson B. 1987. Low plasma selenium as a risk factor for cancer death in middle-aged men. Nut Cancer 10:221-229.
27. Fleshner NE. 2002. Vitamin E and prostate cancer. Urol Clin North Am 29:107-113.
28. Foster SJ, Kraus RJ, Ganther HE. 1986. The metabolism of selenomethionine, Se-methylselenocysteine, their selenonium derivatives, and trimethylselenonium in the rat. Arch Biochem Biophys 251(1):77-86.
29. Ganther HE. 1999. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: Complexities with thioredoxin reductase. Carcinogenesis 20(9):1657-1666.
30. Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, Rosner B, Speizer FE, Willett WC, Hunter DJ. 1995. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87:497-505.
31. Gasparian AV, Yao YJ, Lèu J, Yemelyanov AY, Lyakh LA, Slaga TJ, Budunova IV. 2002. Selenium compounds inhibit I kB kinase (IKK) and nuclear factor-kB (NF-kB) in prostate cancer cells. Mol Cancer Therap 1(12):1079-1087.
32. Gatling RR. 1990. Prostate carcinoma: An autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology. South Med J 83:782-784.
33. Gladyshev VN, Factor VM, Housseau F, Hatfield DL. 1998. Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Biochem Biophys Res Commun 251(2):488-493.
34. Godley PA. 1999. Prostate cancer screening: Promise and peril - A review. Cancer Detect Prev 23:316-324.
35. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS. 2001. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 10:1069-1076.
36. Guttenplan JB, Kosinska W, von Pressentin MM, Rosa J, El-Bayoumy K. 2002. Effects of 1,4-phenylenebis(methylene)selenocyanate (p-XSC) and vitamin E on 4-nitroquinoline-N-oxide (4-NQO)-induced mutagenesis in lacZ mouse upper aerodigestive tissue. Mutat Res 518:85-93.
37. Kanada K, Satoh S, Sawamura D, Hashimoto I, Katabira Y. 1986. The inhibitory effect of selenium on mice inoculated with B16 melanoma cells. J Dermatol 13:19-23.
38. He Q, Rashid A, Rong R, Hillman MJ, Huang Y, Sheikh MS. 2002. Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther 1(3):287-290.
39. Holmgren A. 1995. Thioredoxin structure and mechanism: Conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 3(3):239-243.
40. Hsieh HS, Ganther HE. 1975. Acid-volatile selenium formation catalyzed by glutathione reductase. Biochemistry 14(8):1632-1636.
41. Ip C, Hayes C, Budnick RM, Ganther HE. 1991. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51(2):595-600.
42. Ip C, Thompson HJ, Zhu Z, Ganther HE. 2000. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60(11):2882-2886.
43. Itoh M, Suzuki KT. 1997. Effects of dose on the methylation of selenium to monomethylselenol and trimethylselenonium ion in rats. Arch Toxicol 71(7):461-466.
44. Jackson ML. 1988. Selenium: Geochemical distribution and associations with human heart and cancer death rates and longevity in China and the United States. Biol Trace Elem Res 15:13-21.
45. Jiang C, Ganther H, Lu J. 2000. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation. Mol Carcinog 29(4):236-250.
46. Jiang C, Wang Z, Ganther H, Lu J. 2001. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 61(7):3062-3070.
47. Jiang C, Wang Z, Ganther H, Lu J. 2002. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Therap 1(12):1059-1066.
48. Kayanoki Y, Fujii J, Islam KN, Suzuki K, Kawata S, Matsuzawa Y, Taniguchi N. 1996. The protective role of glutathione peroxidase in apoptosis induced by reactive oxygen species. J Biochem 119(4):817-822.
49. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C. 2000. SELECT: The selenium and vitamin E cancer prevention trial: Rationale and design. Pros Cancer Pros Dis 3:145-151.
50. Knekt P. 1993. Vitamin E and smoking and the risk of lung cancer. Ann NY Acad Sci 686:280-287.
51. Knekt P, Aromaa A, Maatela J, Alfthan G, Aaran RK, Hakama M, Hakulinen T, Peto R, Teppo L. 1990. Serum selenium and subsequent risk of cancer among Finnish men and women. J Nat Cancer Inst 82:864-868.
52. Kobayashi Y, Ogra Y, Ishiwata K, Takayama H, Aimi N, Suzuki KT. 2002. Selenosugars are key and urinary metabolites for selenium excretion within the required to low-toxic range. Proc Nat Acad Sci USA 99(25):15932-15936.
53. Kok FJ, van Duijn CM, Hofman A, Vermeeren R, de Bruijn AM, Valkenburg HA. 1987. Micronutrients and the risk of lung cancer. N Engl J Med 316:1416.
54. Kuiper GG, Klootwijk W, Visser TJ. 2003. Substitution of cysteine for selenocysteine in the catalytic center of type III iodothyronine deiodinase reduces catalytic efficiency and alters substrate preference. Endocrinology 144(6):2505-2513.
55. Lee SR, Bar-Noy S, Kwon J, Levine RL, Stadtman TC, Rhee SG. 2000. Mammalian thioredoxin reductase: Oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Nat Acad Sci USA 97(6):2521-2526.
56. Leinfelder W, Zehelein E, Mandrand-Berthelot MA, Bèock A. 1988. Gene for a novel tRNA species that accepts L-serine and cotranslationally inserts selenocysteine. Nature 331(6158):723-725.
57. Liu YH, Tian HS, Wang DX. 1987. Inhibitory effect of selenium yeast on the metastasis of Lewis lung carcinoma in C57BL mice. Studies with reference of histochemistry and ultrastructure. Chin Med J 100:549-554.
58. Lu YP, Lou YR, Yen P, Newmark HL, Mirochnitchenko OI, Inouye M, Huang MT. 1997. Enhanced skin carcinogenesis in transgenic mice with high expression of glutathione peroxidase or both glutathione peroxidase and superoxide dismutase. Cancer Res 57(8):1468-1474.
59. Marte BM, Downward J. 1997. PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 22(9):355-358.
60. Menter DG, Sabichi AL, Lippman SM. 2000. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prevr 9(11):1171-1182.
61. Navarro-Alarcon M, Lopez-Martinez MC. 2000. Essentiality of selenium in the human body: Relationship with different diseases. Sci Total Environ 249:347-371.
62. Nelson MA, Reid M, Duffield-Lillico AJ, Marshall JR. 2002. Prostate cancer and selenium. Urol Clin N Am 29:67-70.
63. Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S. 2003. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 300:357-363.
64. Nivens AS, Herman J, Pweinrich S, Weinrich MC. 2001. Cues to participation in prostate cancer screening: A theory for practice. Oncol Nurse Forum 28:1449-1456.
65. Pang L, Sawada T, Decker SJ, Saltiel AR. 1995. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 270(23):13585-13588.
66. Park HS, Park E, Kim MS, Ahn K, Kim IY, Choi EJ. 2000. Selenite inhibits the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism. J Biol Chem 275:2527-2531.
67. Peleg I, Morris S, Hames CG. 1985. Is serum selenium a risk factor for cancer? Med Oncol Tumor Pharmacother 2:157-163.
68. Perkins JJ, Sanson-Fisher RW, Clarke SJ, Youman P. 1998. An exploration of screening practices for prostate cancer and the associated community expenditure. B J Urol 82:524-529.
69. Poirier KA, Milner JA. 1983. Factors influencing the antitumorigenic properties of selenium in mice. J Nutr 113:2147-2154.
70. Popova NV. 2002. Perinatal selenium exposure decreases spontaneous liver tumorigenesis in CBA mice. Cancer Lett 179:39-42.
71. Prokopczyk B, Amin S, Desai DH, Kurtzke C, Upadhyaya P, El-Bayoumy K. 1997. Effects of 1,4-phenylenebis(methylene)selenocyanate and selenomethionine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mouse lung. Carcinogenesis 18:1855-1857.
72. Prokopczyk B, Rosa JG, Desai D, Amin S, Sohn OS, Fiala ES, El-Bayoumy K. 2000. Chemoprevention of lung tumorigenesis induced by a mixture of benzo(a)pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by the organoselenium compound 1,4-phenylenebis(methylene)selenocyanate. Cancer Lett 161:35-46.
73. Pumiglia KM, Decker SJ. 1997. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Nat Acad Sci USA 94(2):448-452.
74. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, Roe D, Payne CM, Nelson MA. 1998. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 125(1-2):103-110.
75. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR. 2002. Selenium supplementation and lung cancer incidence: An update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev 11:1285-1291.
76. Ringstad J, Jacobsen BK, Tretli S, Thomassen Y. 1988. Serum selenium concentration associated with risk of cancer. J Clin Pathol 41:454-457.
77. Roehl KA, Antenor JA, Catalona WJ. 2002. Serial biopsy results in prostate cancer screening study. J Urol 167:2435-2439.
78. Salonen JT, Alfthan G, Huttunen JK, Puska P. 1984. Association between serum selenium and the risk of cancer. Am J Epidem 120:342-349.
79. Schrauzer GN, White DA, Schneider CJ. 1976. Inhibition of the genesis of spontaneous mammary tumors in C3H mice: Effects of selenium and of selenium-antagonistic elements and their possible role in human breast cancer. Bioinorg Chem 6:265-270.
80. Schrauzer GN, White DA, Schneider CJ. 1977a. Cancer mortality correlation studies-III: Statistical associations with dietary selenium intakes. Bioinorg Chem 7:23-31.
81. Schrauzer GN, White DA, Schneider CJ. 1977b. Cancer mortality correlation studies-IV: Associations with dietary intakes and blood levels of certain trace elements, notably Se-antagonists. Bioinorg Chem 7:35-56.
82. Schroeder HA, Mitchener M. 1972. Selenium and tellurium in mice. Effects on growth, survival, and tumors. Arch Environ Health 24:66-71.
83. Seo YR, Kelley MR, Smith ML. 2002. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Nat Acad Sci USA 99:14548-14553.
84. Shamberger RJ, Frost DV. 1969. Possible protective effect of selenium against human cancer. Can Med Assoc J 100:682.
85. Shiobara Y, Yoshida T, Suzuki KT. 1998. Effects of dietary selenium species on Se concentrations in hair, blood, and urine. Toxicol App Pharmacol 152(2):309-314.
86. Simon HU, Haj-Yehia A, Levi-Schaffer F. 2000. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5:415-418.
87. Smith DS, Catalona WJ, Herschman JD. 1996. Longitudinal screening for prostate cancer with prostate-specific antigen. J Am Med Assoc 276:1309-1315.
88. Stadtman TC. 1991. Biosynthesis and function of selenocysteine-containing enzymes. J Biol Chem 266(25):16257-16260.
89. Stapleton SR, Garlock GL, Foellmi-Adams L, Kletzien RF. 1997. Selenium: Potent stimulator of tyrosyl phosphorylation and activator of MAP kinase. Biochimica et Biophysica Acta 1355(3):259-269.
90. Stein B, Lindenmayer JM. 1997. Proposed prostate cancer screening recommendations. Med Heal Rhode I 80:343-345.
91. Sunde RA. 1990. Molecular biology of selenoproteins. Ann Re Nut 10:451-474.
92. Temple NJ, Basu TK. 1987. Selenium and cabbage and colon carcinogenesis in mice. J Nat Cancer Inst 79:1131-1134.
93. Tom J. 2002. SELECT (opportunity for prostate cancer prevention). Hawaii Med J 61:126-129.
94. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. 1992. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 288:351-355.
95. Uzgare AR, Kaplan PJ, Greenberg NM. 2003. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Pros 55(2):128-139.
96. Virtamo J, Valkeila E, Alfthan G, Punsar S, Huttunen JK, Karvonen MJ. 1987. Serum selenium and risk of cancer. A prospective follow-up of nine years. Cancer 60:145-148.
97. Vogt TM, Ziegler RG, Graubard BI, Swanson CA, Greenberg RS, Schoenberg JB, Swanson GM, Hayes RB, Mayne ST. 2003. Serum selenium and risk of prostate cancer in US Blacks and Whites. Int J Cancer 103:664-670.
98. Voss JD, Schectman JM. 2001. Prostate cancer screening practices and beliefs. J Gen Int Med 16:831-837.
99. Wang Z, Jiang C, Lèu J. 2002. Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcin 34(3):113-120.
100. Wang Z, Zhang B, Wang M, Carr BI. 2003. Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein J Biol Chem 278:11138-11144.
101. Ward JE, Hughes AM, Hirst GH, Winchester L. 1997. Men's estimates of prostate cancer risk and self-reported rates of screening. Med J Aust 167:250-253.
102. Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF, Jr., Glickman LT, Oteham C, Schlittler D, Morris JS. 2003. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Nat Cancer Inst 95(3):237-241.
103. Watrach AM, Milner JA, Watrach MA, Poirier KA. 1984. Inhibition of human breast cancer cells by selenium. Cancer Lett 25:41-47.
104. Wattenberg LW. 1974. Potential inhibitors of colon carcinogenesis. Am J Dig Dis 19:947-953.
105. Webber MM, Perez-Ripoll EA, James GT. 1985. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 130(2):603-609.
106. Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider K, Hames CG. 1983. Prediagnostic serum selenium and risk of cancer. Lancet 2:130-134.
107. Yang SZ, Abdulkadir SA. 2003. Early growth response genel modulates androgen receptor signaling in prostate carcinoma cells. J Biol Chem 278:39906-39911.
108. Yang X, Tian Y, Ha P, Gu L. 1997. Determination of the selenomethionine content in grain and human blood. J Hyg Res 26(2):113-116.
109. Yu SY, Chu YJ, Li WG. 1988. Selenium chemoprevention of liver cancer in animals and possible human applications. Biol Trace Elem Res 15:231-241.
110. Yu A, Somasundar P, Balsubramaniam A, Rose AT, Vona-Davis L, McFadden DW. 2002. Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor. J Surg Res 105:65-68.
111. Zhong L, Holmgren A. 2000. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem 275(24):18121-18128.